Standard BioTools Inc
NASDAQ:LAB
Intrinsic Value
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. [ Read More ]
The intrinsic value of one LAB stock under the Base Case scenario is 3.84 USD. Compared to the current market price of 2.36 USD, Standard BioTools Inc is Undervalued by 39%.
Valuation Backtest
Standard BioTools Inc
Run backtest to discover the historical profit from buying and selling LAB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Standard BioTools Inc
Current Assets | 158.2m |
Cash & Short-Term Investments | 114.9m |
Receivables | 19.7m |
Other Current Assets | 23.7m |
Non-Current Assets | 164.9m |
PP&E | 54.9m |
Intangibles | 107.7m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 109.3m |
Accounts Payable | 9.2m |
Accrued Liabilities | 25.3m |
Other Current Liabilities | 74.7m |
Non-Current Liabilities | 50.5m |
Long-Term Debt | 4m |
Other Non-Current Liabilities | 46.6m |
Earnings Waterfall
Standard BioTools Inc
Revenue
|
106.3m
USD
|
Cost of Revenue
|
-55.9m
USD
|
Gross Profit
|
50.5m
USD
|
Operating Expenses
|
-113.5m
USD
|
Operating Income
|
-63m
USD
|
Other Expenses
|
-11.6m
USD
|
Net Income
|
-74.7m
USD
|
Free Cash Flow Analysis
Standard BioTools Inc
LAB Profitability Score
Profitability Due Diligence
Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Standard BioTools Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
LAB Solvency Score
Solvency Due Diligence
Standard BioTools Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Standard BioTools Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LAB Price Targets Summary
Standard BioTools Inc
According to Wall Street analysts, the average 1-year price target for LAB is 3.65 USD with a low forecast of 3.28 USD and a high forecast of 4.2 USD.
Ownership
LAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LAB Price
Standard BioTools Inc
Average Annual Return | -25.54% |
Standard Deviation of Annual Returns | 69.76% |
Max Drawdown | -93% |
Market Capitalization | 902.6m USD |
Shares Outstanding | 382 460 992 |
Percentage of Shares Shorted | 2.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Contact
IPO
Employees
Officers
The intrinsic value of one LAB stock under the Base Case scenario is 3.84 USD.
Compared to the current market price of 2.36 USD, Standard BioTools Inc is Undervalued by 39%.